Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNP520 prevention trial in participants at risk for Alzheimer's disease
2016-002976-28Phase 2Terminated
- Sponsor
- Novartis
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of umibecestat in Alzheimer's disease (AD) (3 arms), sponsored by Novartis. Primary endpoint: Time to first diagnosis of MCI due to Alzheimer's disease or Alzheimer's dementia. Started Mar 2017; status: terminated.
02
Drugs
umibecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2016-002976-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002976-28.